Trial Profile

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UTAA-09/17-gamma-delta-T-cell-therapy PersonGen Biotherapeutics (Primary)
Indications Autoimmune disorders; Idiopathic thrombocytopenic purpura; Interstitial lung diseases; Myositis; Primary biliary cirrhosis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma
Focus Adverse reactions
Sponsors PersonGen Biotherapeutics

Most Recent Events

16 Apr 2024 New trial record
12 Apr 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com